


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on March 18, 2005

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney



ifw
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1632
Patent Application
Docket No. USF-212XZ1T
Serial No. 10/709,801

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1632
Applicants : Caroline Despons, Joseph Wahle, John M. Ninos, William G. Kerr
Serial No. : 10/709,801
Filed : May 28, 2004
For : Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicants have not submitted copies of the U.S. patents or published U.S. applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig
Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100


Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (6 pages); copies of some references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/709,801	
			Filing Date	May 28, 2004	
			First Named Inventor	Caroline Despons	
			Art Unit	1632	
			Examiner Name		
Sheet	1	of	6	Attorney Docket Number	USF-212XZ1T

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-10/605,452	09-30-2003	Kerr et al.	All
	U2	US-10/904,667	11-22-2004	Kerr et al.	All
	U3	US-2002/0137711 A1	09-26-2002	Kerr	All
	U4	US-2002/0165192 A1	11-07-2002	Kerr et al.	All
	U5	US-4,603,112	07-29-1986	Paoletti et al.	All
	U6	US-4,769,330	09-06-1988	Paoletti et al.	All
	U7	US-4,777,127	10-11-1988	Suni et al.	All
	U8	US-5,017,487	05-21-1991	Stunnenberg et al.	All
	U9	US-5,166,057	11-24-1992	Palese et al.	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 89/01973 A2	03-09-1989	Applied Biotech. Inc.	All	
	F2	WO 91/02805 A2	03-07-1991	Viagene, Inc.	All	
	F3	WO 92/06693 A1	04-30-1992	Fox Chase Cancer Ctr.	All	
	F4	WO 97/10252 A1	03-20-1997	Fred Hutchinson Cancer Research	All	
	F5	WO 97/12039 A2	04-03-1997	Krystal	All	
	F6	EP 0 345 242 A2	12-06-1989	Smithkline Biologicals	All	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/709,801	
				Filing Date	May 28, 2004	
				First Named Inventor	Caroline Desports	
				Art Unit	1632	
Examiner Name						
Sheet	2	of	6	Attorney Docket Number	USF-212XZ1T	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U10	US-6,090,621	07-18-2000	Kavanaugh et al.	All
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	F7	EP 0 440 219 A1		08-07-1991	Schwiz, Serum- & Impfinstitut Bern	All	
	F8	GB 2 200 651		08-10-1988	Khalaf Al-Sumidale	All	
	F9						
	F10						
	F11						
	F12						

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Despons
				Group Art Unit	1632
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AGRAWAL, S. "Antisense oligonucleotides: towards clinical trials" <i>TIBTECH</i> , 1996, 14:376-387.	
	R2	AGRAWAL, S. and KANDIMALLA, E. "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , 2000, 6:72-81.	
	R3	AKAGI, K. <i>et al.</i> "Cre-mediated somatic site-specific recombination in mice" <i>Nucleic Acids Res</i> , 1997, 25(9):1766-1773.	
	R4	BENDER, M.A. <i>et al.</i> "Description and targeted deletion of 5' hypersensitive site 5 and 6 of the mouse β -globin locus control region" <i>Blood</i> , 1998, 92:4394-4403.	
	R5	BRAASCH, D.A. and COREY, D.R. "Novel antisense and peptide nucleic acid strategies for controlling gene expression" <i>Biochemistry</i> , 2002, 41(14):4503-4510.	
	R6	BRANCH, A. "A good antisense molecule is hard to find" <i>Trends in Biochem.</i> , 1998, 23:45-50.	
	R7	CANTLEY, L.C. <i>et al.</i> "Oncogenes and signal transduction" <i>Cell</i> , 1991, 64:281-302.	
	R8	CHIRILA, T. <i>et al.</i> "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides" <i>Biomaterials</i> , 2002, 23:321-342.	
	R9	CROOKE, S.T. "Basic principles of antisense therapeutics" in <i>Antisense Res. and Application</i> , chapter 1, pgs 1-50, S. Crooke, Ed., Springer-Verlag, 1999.	
	R10	DESPONTS, C. <i>et al.</i> "MHC class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival" <i>FASEB Journal</i> , March 20, 2002, 16(4):A706, abstract.	
	R11	EVANS, D.J. <i>et al.</i> "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies" <i>Nature</i> , 1989, 339:385-388.	
	R12	FISHER-HOCH, S.P. <i>et al.</i> "Protection of rhesus monkeys from fatal Lassa fever by vaccination with recombinant vaccinia virus containing the Lassa virus glycoprotein gene" <i>PNAS</i> , 1989, 86:317-321.	
	R13	GEWIRTZ, A.M. <i>et al.</i> "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise" <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:3161-3163.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/709,801
Filing Date	May 28, 2004
First Named Inventor	Caroline Despots
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	USF-212XZ1T

Sheet	4	of	6
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	GHANSAH, T. <i>et al.</i> "A role for the SH2-containing inositol phosphatase in the biology of natural killer cells and stem cells" <i>Activating and Inhibitory Immunoglobulin-like Receptors</i> , 2001, pp. 129-140.	
	R15	GHANSAH, T. <i>et al.</i> "Target disruption of Src homology 2-containing 5' inositol phosphatase (SHIP) alters PI3K/AKT and MAPK signal transduction pathways in murine natural killer cells" <i>FASEB Journal</i> , March 20, 2002, 16(4):A706, abstract.	
	R16	GHANSAH, T. <i>et al.</i> "The Src homology 2 containing inositol phosphatase is vital for the function and homeostatis of Natural Killer cells" <i>FASEB Journal</i> , March 7, 2001, 15(4):A655, abstract.	
	R17	GUZMAN, R.J. <i>et al.</i> "Molecular and cellular cardiology/receptors: efficient and selective adenovirus-mediated gene transfer into vascular neointima" <i>Circulation</i> , 1993, 88(6):2838-2848.	
	R18	HAWKINS, P.T. <i>et al.</i> "Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P ₃ by activating a PtdIns(4,5)P ₂ 3-OH kinase" <i>Nature</i> , 1992, 358:157-910.	
	R19	HELD, W. <i>et al.</i> "Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection" <i>J. Exp. Med.</i> , 1996, 184(5):2037-2041.	
	R20	HELGASON, C.D. <i>et al.</i> "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span" <i>Genes & Dev.</i> , 1998, 12(11):1610-1620.	
	R21	HUBER, M. <i>et al.</i> "The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation" <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95(19):11330-11335.	
	R22	JEFFERSON, A.B. <i>et al.</i> "Properties of type II inositol polyphosphate 5-phosphatase" <i>J. Biol. Chem.</i> , 1995, 270(16):9370-9377.	
	R23	JEN, K-Y and GEWIRTZ, A.M. "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies" <i>Stem Cells</i> , 2000, 18:307-319.	
	R24	JOLLY, D. <i>et al.</i> "Viral vector systems for gene therapy" <i>Cancer Gene Therapy</i> , 1998, 1(1):51-64.	
	R25	KASS-EISLER, A. <i>et al.</i> "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo" <i>PNAS</i> , 1993, 90:11498-11502.	
	R26	KERR, WILLIAM G. <i>et al.</i> , Critical Role for SHIP in engraftment of histo-incompatible stem cells, <i>Oncology Research</i> , 2001, 12:285.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Desports
				Group Art Unit	1632
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	KLIPPEL, A. <i>et al.</i> "Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways" <i>Mol. Cell. Biol.</i> , 1996, 16(8):4117-4127.	
	R28	KOH, C. <i>et al.</i> "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo" <i>Blood</i> , 2001, 97(10):3132-3137.	
	R29	KOLLS, J. <i>et al.</i> "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer" <i>PNAS</i> , 1994, 91:215-219.	
	R30	LANIER, L.L. "NK cell receptors" <i>Annual Rev of Immunology</i> , 1998, 16:359-393.	
	R31	LIU, L. <i>et al.</i> "The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis" <i>J. Biol. Chem.</i> , 1997, 272:8983-8988.	
	R32	LIU, Q. <i>et al.</i> "SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation any myeloid cell-survival" <i>Genes & Dev.</i> , 1999, 13(7):786-791.	
	R33	LIU, Q. <i>et al.</i> "The inositol polyphosphate 5-phosphatase SHIP is a crucial negative regulator of B cell antigen receptor signaling" <i>J. Exp. Med.</i> , 1998, 188(7):1333-1342.	
	R34	LOTZOVA, E. <i>et al.</i> "Prevention of Rejection of Allogeneic Bone Marrow Transplants by NK-1.1 Anti Serum" <i>Transplantation</i> , 1983, 35(5):490-494.	
	R35	LUCAS, D.M. and ROHRSCHEIDER, L. "A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development" <i>Blood</i> , 1999, 93(6):1922-1933	
	R36	OKADA, H. <i>et al.</i> "Cutting edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca ²⁺ oscillatory response" <i>J. Immunol.</i> , 1998, 161:5192-5132.	
	R37	OVERBAUGH, J. <i>et al.</i> "Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats" <i>Science</i> , 1988, 239:906-910.	
	R38	PALU, G. <i>et al.</i> "In pursuit of new developments for gene therapy of human diseases" <i>J. Biotech</i> , 1999, 68:1-13.	
	R39	PIHL-CAREY, K. "Disease drug fails in phase III" <i>BioWorld Today</i> , 1999, 10:1-2.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/709,801		
		Filing Date	May 28, 2004		
		First Named Inventor	Caroline Despons		
		Group Art Unit	1632		
		Examiner Name			
Sheet	6	of	6	Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	POZNANSKY, M. <i>et al.</i> "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector" <i>J. Virol.</i> , 1991, 65:532-536.	
	R41	RUGGERI, L. <i>et al.</i> "Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation" <i>Blood</i> , 1999, 94(1):333-339.	
	R42	SABIN, A.B. and BOULGER, L.R. "History of Sabin attenuated poliovirus oral live vaccine strains" <i>J. of Biol. Standardization</i> , 1973, 1:115-118.	
	R43	SAMULSKI, R.J. <i>et al.</i> "Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression" <i>J. Vir.</i> , 1989, 63(9):3822-3828.	
	R44	STEPHENS, L.R. <i>et al.</i> "Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signaling system?" <i>Biochim. Biophys Acta</i> , 1993, 1179:27-75.	
	R45	TAMM, I. <i>et al.</i> "Antisense therapy in oncology: new hope for an old idea?" <i>The Lancet</i> , 2001, 358:489-497.	
	R46	WANG, C.Y. and HUANG, L. "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse" <i>PNAS</i> , 1987, 84:7851-7855.	
	R47	WANG, J-W. <i>et al.</i> "Influence of ZSHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation" <i>Science</i> , 2002, 295(5562):2094-2097.	
	R48	WOLF, I <i>et al.</i> "Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110-kDa splice isoform, SHIP6" <i>Genomics</i> , 2000, 69(1):104-112.	
	R49	YOKOYAMA, W.M. "Natural killer cell receptors" <i>Current Opin in Immunology</i> , 1998, 10(3):298-305.	
	R50		
	R51		
	R52		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.